| nivolumab based treatment |
| nivolumab alone |
mHNSCC - (neo)adjuvant (NA) | |
mHNSCC - 1st line (L1) | |
mHNSCC - L1 - all population 2 | |
mHNSCC - L1 - PDL1 positive 4 | |
mHNSCC - 2nd line (L2) | |
mHNSCC - L2 - all population 4 | |
mHNSCC - L2 - PDL1 negative 2 | |
mHNSCC - L2 - PDL1 positive 1 | |